CT Volumetry Biomarker Ctte
This Wiki is for collaborative creation of QIBA's Volumetric CT Technical Committee materials and ongoing activities.
Mission: Investigate the technical feasibility and medical value of quantifying longitudinal changes in volume with CT.
- Characterize the precision and accuracy of volumetric tumor measurements.
- This will be an essential prelude for understanding the threshold that will be needed to classify longitudinal changes in tumor volume as medically meaningful surrogates for changes in health status.
- Compare the sensitivity of volumetric measurements to RECIST/ World Health Organization (WHO) (conventional & modified) outcome measures.
- This will be necessary in order to determine if Progressive Disease can be detected significantly sooner with volumetric techniques than with uni- or bi-dimensional line-lengths placed on a single slice.
In a graphic, therapy assessment looks like this (this slide and the two following courtesy R. Avila):
The present defacto standard applies the following methodolgy:
Our goals are to address bias and variance, which in turn outght to allow shorter trials and/or lower enrollments:
To accomplish this, we adopt the following flow which represents the structure of our effort as well as the resulting output we achieve:
Quantitative Response Metrics for Lung Cancer was selected as a useful concrete focus to get started.
Write Profile documents to which equipment and sites can conform to accomplish Quantification goals.
- Profile Strategy for Vol CT
Validate key concepts and answer key questions needed to write the Profiles and demonstrate their effectiveness.
- VolCT - Group 1A - Analyze Bias/Variance where Ground Truth is Known Deterministically
- VolCT - Group 1B - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings
- VolCT - Group 1C - Model Sources of Variability from a Systems Engineering Analysis
- VolCT - Group 2 - Set Standards for using Volumetric Imaging in Clinical Trials
- Initial Target Selection - describing the early prioritization discussions and settling on Lung Tumor Volumes
- Sources of Variability - Andrew Buckler
- Validation Roadmap - P. David Mozley, MD
- Process Groundwork & Profiling - Kevin O'Donnell - See also the Wiki Version